SPIRE SIGN IN Register

Spirethoughts

Spire's six most recent Spirethoughts.

Refilling to reduce the global plastic binge
Crude oil prices and the environment
Productivity & Efficiency – the new WFH buzzwords
Will Smart Health & Safety products ride Covid-19’s coattails?
Will Smart Health & Safety products ride Covid-19’s coattails?
Awareness and adoption of Sustainable Smart Technology
Technology security and privacy concerns have become critical to consumers
Technology security and privacy concerns have become critical to consu...

India’s generic drug industry heading for change

The India Supreme Court recently rejected drug maker Novartis AG’s attempt to patent an updated version of a cancer drug. This would ensure patients across the globe would have access to cheaper versions of lifesaving medicines, such as Glivec, that is used to treat chronic myeloid leukemia. With a generic and more affordable medicine available at a huge price difference, this could be the difference between life and death.

On the other hand, this decision also means that India’s USD26 billion generic drug industry, which supplies most cheap medicines across the developing world could slow down. Many other international pharmaceutical companies are now re-thinking their strategies for the Indian market. Nonetheless, it signifies that Indian companies will now have added legal coverage to produce and export low-cost generic drugs.

How would giving the world access to cheaper medicines affect India?

Back to Top

Back to Home
BTBTBTBTBTBT